Most cited papers from OREGA Biotech (France)

OREGA Biotech (France)

What are the most cited papers from OREGA Biotech (France)?

The most cited paper from OREGA Biotech (France) is "Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies" (Ivan Perrot et al., 2019), with 430 citations. Next come "Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen" (267) and "Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity" (255).

Published TypeFieldAccessCitations

Showing 21 of 21 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies Ivan Perrot et al. · Cell Reports Open access	May 2019	430
2	Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen Emeric Limagne, Romain Euvrard, Marion Thibaudin et al. · Cancer Research	5 Aug 2016	267
3	Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity Jérémy Bastid, Anne Regairaz, Nathalie Bonnefoy et al. · Cancer Immunology Research	17 Nov 2014	255
4	ENTPD1/CD39 is a promising therapeutic target in oncology Jérémy Bastid, A Cottalorda-Regairaz, Gilles F. Alberici et al. · Oncogene	2 Jul 2012	202
5	Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type Joseph Fabre, Jérôme Giustiniani, Christian Garbar et al. · International Journal of Molecular Sciences Open access	30 Aug 2016	172
6	IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2 Stéphanie Cochaud, Jérôme Giustiniani, Clémence Thomas et al. · Scientific Reports Open access	9 Dec 2013	153
7	EMT in carcinoma progression and dissemination: Facts, unanswered questions, and clinical considerations Jérémy Bastid · Cancer and Metastasis Reviews Review	3 Jan 2012	102
8	The Emerging Role of the IL-17B/IL-17RB Pathway in Cancer Jérémy Bastid, Cécile Déjou, Aurélie Docquier et al. · Frontiers in Immunology Open access	21 Apr 2020	87
9	The Interleukin-17 Family of Cytokines in Breast Cancer Joseph Fabre, Jérôme Giustiniani, Christian Garbar et al. · International Journal of Molecular Sciences Open access	4 Dec 2018	73
10	Regulatory T Cells from Colon Cancer Patients Inhibit Effector T-cell Migration through an Adenosine-Dependent Mechanism Patrik Sundström, Hanna Stenstad, Veronica Langenes et al. · Cancer Immunology Research Open access	19 Jan 2016	73
11	IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells Sarah Mombelli, Stéphanie Cochaud, Yacine Merrouche et al. · Scientific Reports Open access	8 Jul 2015	59
12	The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway Emilie Laprévotte, Stéphanie Cochaud, Stanislas du Manoir et al. · Oncotarget Open access	6 Dec 2017	52
13	CD 39 is involved in mediating suppression by M ycobacterium bovis BCG ‐activated human CD 8+ CD 39+ regulatory T cells Mardi C. Boer, Krista E. van Meijgaarden, Jérémy Bastid et al. · European Journal of Immunology Open access	22 Apr 2013	43
14	Lymphocyte-derived interleukin-17A adds another brick in the wall of inflammation-induced breast carcinogenesis Jérémy Bastid, Nathalie Bonnefoy, Jean‐François Eliaou et al. · OncoImmunology Open access	27 Mar 2014	41
15	CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression Nathalie Bonnefoy, Jérémy Bastid, Gilles F. Alberici et al. · OncoImmunology Open access	3 Feb 2015	39
16	IL-21 promotes the development of a CD73-positive Vγ9Vδ2 T cell regulatory population Clément Barjon, Henri‐Alexandre Michaud, Angeline Fages et al. · OncoImmunology Open access	14 Sep 2017	36
17	IL-17E synergizes with EGF and confersin vitroresistance to EGFR-targeted therapies in TNBC cells Yacine Merrouche, Joseph Fabre, Hervé Curé et al. · Oncotarget Open access	23 Jul 2016	30
18	Increased degradation of ATP is driven by memory regulatory T cells in kidney transplantation tolerance Maxim Durand, Florian Dubois, Cécile Déjou et al. · Kidney International Open access	15 Feb 2018	16
19	Immunopathologie du psoriasis Adèle de Masson, Jean‐David Bouaziz, Maxime Battistella et al. · médecine/sciences Open access	Mar 2016	10
20	New effective and less painful high frequency electrochemotherapy protocols: From optimization on 3D models to pilot study on veterinary patients Alexia de, Jean-Baptiste Leroy, Loïck Royant et al. · Journal of Controlled Release	2 Mar 2025	4
21	Une nouvelle génération d’immunothérapies ciblant la voie CD39/CD73/adénosine pour favoriser la réponse immunitaire anti-tumorale Laurent Gros, Carine Paturel, Ivan Perrot et al. · médecine/sciences Open access	Feb 2020	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.